Aligos-Amoytop $445M HBV Licensing Deal Expands Access

SOUTH SAN FRANCISCO, Calif., April 16, 2026

Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech to develop and commercialize its HBV drug candidate pevifoscorvir sodium in Greater China, in a deal valued at up to $445 million, including upfront and milestone payments. The agreement marks a significant step in advancing chronic hepatitis B (HBV) treatment innovation, enabling broader access to novel antiviral therapies while strengthening global commercialization strategies.

Strategic Licensing to Accelerate HBV Drug Development

In a major strategic move, Aligos will receive $25 million upfront and is eligible for up to $420 million in clinical, regulatory, and commercial milestones, along with tiered royalties on future sales. Amoytop will lead development and commercialization across Greater China, including Mainland China, Hong Kong, Taiwan, and Macau, while Aligos retains rights in global markets such as the United States and Europe.

This partnership leverages Amoytop’s strong hepatology market presence and positions the therapy for accelerated development in a region with over 90 million people living with HBV, highlighting the significant unmet medical need.

Novel HBV Drug Targets Full Viral Lifecycle

Pevifoscorvir sodium is a next-generation capsid assembly modulator (CAM-E) designed to target multiple stages of the HBV lifecycle. The therapy demonstrates a dual mechanism of action, enabling it to block viral replication, prevent HBV DNA integration, and reduce cccDNA reservoirs, which are critical for long-term viral suppression.

Early clinical data shows strong antiviral activity, favorable safety profile, and promising pharmacokinetics, positioning it as a potential first- and best-in-class therapy. The drug is currently being evaluated in the Phase 2 B-SUPREME clinical trial, with interim data expected in 2026 and topline results anticipated in 2027.

Global Expansion and Combination Therapy Potential

The collaboration also opens opportunities for combination treatment strategies, particularly with Amoytop’s approved HBV therapies such as PEGBING®, enabling more personalized and effective treatment regimens. In addition, the deal is expected to extend Aligos’ financial runway into late 2026, supporting continued clinical development and pipeline expansion. This partnership builds on an existing relationship between the two companies and reinforces their shared commitment to advancing innovative therapies for liver and viral diseases while addressing a major global health burden.

Source: Aligos, Amoytop press release